Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis in patients undergoing treatment with bimekizumab at labelled dosage for psoriasis, for at least 16 weeks.
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience – IL PSO (Italian Landscape Psoriasis)
Esposito, Maria;Fargnoli, Maria Concetta;
2025-01-01
Abstract
Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis in patients undergoing treatment with bimekizumab at labelled dosage for psoriasis, for at least 16 weeks.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Megna et al. llae400.pdf
solo utenti autorizzati
Tipologia:
Documento in Versione Editoriale
Licenza:
Non specificato
Dimensione
524.89 kB
Formato
Adobe PDF
|
524.89 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
